FTC Official Says Patent Settlement Side Deals Suspicious
Pharmaceutical companies can minimize the risk of facing a Federal Trade Commission probe of their patent settlements by not signing those agreements at the same time as side deals that the...To view the full article, register now.
Already a subscriber? Click here to view full article